Pfizer And Debiopharm Collaborate To Co-Develop Investigational Compound Tremelimumab (CP-675,206) In Advanced Melanoma

Main Category: Melanoma / Skin Cancer
Also Included In: Cancer / Oncology;  Dermatology;  Clinical Trials / Drug Trials
Article Date: 11 Jan 2010 - 4:00 PDT

email to a friend   printer friendly   opinions  

Pfizer Inc. (Pfizer) and Debiopharm Group™ (Debiopharm) announced today that they have entered into a co-development agreement to conduct a Phase 3 trial of tremelimumab (CP675,206), a fully human anti-CTLA4 monoclonal antibody for the treatment of patients with unresectable, Stage IV melanoma. A biomarker will be used to select patients considered likely to respond to tremelimumab.

Under the terms of the agreement, Debiopharm will assume responsibility for conducting the phase 3 trial of tremelimumab and Pfizer will retain responsibility for worldwide commercialization of the compound.

Melanoma, the deadliest form of skin cancer, occurs in about 69,000 patients in the United States each year, and results in about 9,000 deaths. The number of melanoma cases worldwide is increasing faster than any other cancer.

Pfizer's investigational drug, tremelimumab (CP675,206), currently in phase 2, is a fully human igG2 monoclonal antibody which has been in development for the treatment of advanced melanoma. In April 2008, Pfizer announced that it had discontinued a Phase 3 clinical trial for patients with advanced melanoma after the Data Safety Monitoring Board (DSMB) review of interim data showed that the trial would not demonstrate superiority to standard chemotherapy. Analysis of the data from this trial identified the biomarker which will be used in patient selection for the upcoming trial.

"The continuation of the clinical development of tremelimumab with our partner, Debiopharm, is a demonstration of our commitment to personalized medicine for cancer patients," said Garry Nicholson, president and general manager of Pfizer's Oncology Business Unit. "Debiopharm is a successful company which has achieved impressive results on a global scale. This co-development partnership is an opportunity to leverage the combined expertise of both companies in this innovative endeavour."

Thierry Mauvernay, Executive Vice President, Debiopharm Group™ said, "Debiopharm and Pfizer share the same vision of personalized medicine for the benefit of patients and to enhance the effectiveness of medicine. We are proud to enter into a unique co-development partnership with Pfizer to address the unmet medical needs of Melanoma patients."

Financial terms of the co-development agreement between Debiopharm and Pfizer have not been disclosed.

About Pfizer Oncology

Pfizer Oncology is committed to the discovery, investigation and development of innovative treatment options to improve the outlook for cancer patients worldwide. Our strong pipeline, one of the most robust in the industry, is studied with precise focus on identifying and translating the best scientific breakthroughs into clinical application for patients across a wide range of cancers, including breast, lung, prostate, sarcoma, melanoma, and various hematologic cancers. Pfizer Oncology has more than 25 biologics and small molecules in clinical development and more than 200 clinical trials underway.

By working collaboratively with academic institutions, individual researchers, cooperative research groups, governments, and licensing partners, Pfizer Oncology strives to cure or control cancer with breakthrough medicines, to deliver the right drug for the right patient at the right time.

For more information please visit http://www.Pfizer.com.

Source
Pfizer Inc.
Debiopharm Group™

• Additional
• References
• Citations